Close
Novotech
Jabsco PureFlo 21 Single Use

Chinese Drug Development Fund Gets $500mn Boost In Hong Kong

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...
- Advertisement -

The Hong Kong government announced plans to add $500 million to the Chinese Medicine Development Fund beginning with this fiscal year during a budget speech in order to support the commissioning of large-scale training, research, and publicity projects on strategic themes and to advance more capacity-building programmes for the sector, including making preparations for Hong Kong’s first Chinese medicine hospital, which is expected to commence its operations in 2025, and thereby strengthen the Chinese medicine role when it comes to the primary healthcare system.

Several varied practitioners as well as organizations involved in the Chinese medicine industry have benefited from the rollout of more than ten funding schemes since the Chinese Medicine Development Fund’s formal launch in 2019.

It is well to be noted that at the end of the previous year, the government unveiled the Primary Healthcare Blueprint, which outlines several crucial reform initiatives for enhancing Hong Kong’s primary healthcare services and adopts prevention-oriented, community-based, family-centered, as well as early detection and intervention strategies. The goal of the Blueprint is to improve the general public’s health by developing a sustainable healthcare system and offering comprehensive and coordinated healthcare services.

Apparently, as introduced in the Blueprint, the government will launch the Chronic Disease Co-Care Pilot Scheme and enhance measures to the Elderly Health Care Voucher Scheme. The government is most likely to announce the details in the third quarter of 2023 and reserve enough financial resources for the schemes.

Latest stories

Related stories

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »